Funds and ETFs Catalent, Inc.

CTLT

US1488061029

Name	Weight	AuM	1st Jan change	Investor Rating
BMO MSCI GENOMIC INNOVATION INDEX ETF - CAD	1.35%	2 M€	-.--%
FIRST TRUST ALPHADEX U.S. HEALTH CARE SECTOR INDEX ETF - CAD	1.21%	8 M€	+2.44%
FIRST TRUST ALPHADEX U.S. HEALTH CARE SECTOR INDEX ETF - CAD HEDGED	0.83%	2 M€	+6.77%
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (YEN-HEDGED) ETF - JPY	0.60%	18 M€	+3.79%	-
BMO MSCI INNOVATION INDEX ETF - CAD	0.48%	7 M€	-.--%	-
STERLING CAPITAL DIVERSE MULTI-MANAGER ACTIVE ETF- USD	0.40%	92 M€	+0.06%	-
ARMOR US EQUITY INDEX ETF - USD	0.22%	9 M€	-.--%	-
SYNTAX STRATIFIED TOTAL MARKET II ETF - USD	0.21%	8 M€	+3.41%	-
SYNTAX STRATIFIED U.S. TOTAL MARKET HEDGED ETF - USD	0.21%	33 M€	+0.25%	-
SYNTAX STRATIFIED U.S. TOTAL MARKET ETF - USD	0.21%	18 M€	+3.41%	-
CSIF (IE) MSCI USA ESG LEADERS BLUE UCITS ETF - B - USD	0.09%	2,510 M€	+12.00%
ADVOCATE RISING RATE HEDGE ETF - USD	0.08%	5 M€	-72.95%	-
OSSIAM BLOOMBERG USA PAB UCITS ETF - 1A - EUR HEDGED	0.07%	9 M€	+2.75%	-
OSSIAM BLOOMBERG USA PAB UCITS ETF - 1A (EUR) - EUR	0.07%	736 M€	+6.09%
CSIF (IE) MSCI WORLD ESG LEADERS BLUE UCITS ETF - BH - EUR	0.06%	277 M€	-.--%	-
CSIF (IE) MSCI WORLD ESG LEADERS BLUE UCITS ETF - BH - CHF	0.06%	194 M€	+7.48%	-
CSIF (IE) MSCI WORLD ESG LEADERS BLUE UCITS ETF - B - USD	0.06%	441 M€	+10.26%
NEXT FUNDS S&P 500 ESG INDEX EXCHANGE TRADED FUND - JPY	0.05%	27 M€	+17.28%	-
CSIF (IE) MSCI USA BLUE UCITS ETF B ACC - USD	0.05%	2,658 M€	+10.56%	-
LYXOR MSCI USA CLIMATE CHANGE UCITS ETF - USD	0.04%	36 M€	-.--%
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (UNHEDGED) ETF - JPY	0.04%	273 M€	+15.83%
NEXT FUNDS S&P 500 (UNHEDGED) ETF - JPY	0.04%	61 M€	+17.30%	-
AMUNDI MSCI WORLD ESG LEADERS SELECT - UCITS ETF DR (C) - USD	0.03%	276 M€	+11.40%	-
LEVERAGE SHARES 3X LONG TOTAL WORLD ETP SECURITIES - USD	0.03%	0 M€	0.00%	-

Catalent, Inc. is specialized in pharmaceutical outsourcing services. The group offers solutions for the development and formulation of drugs, biological products and animal health products. Net sales break down by activity as follows: - provision of development services and clinical supply services (55.4%); - subcontracted manufacturing services (44.6%). Net sales are distributed geographically as follows: the United States (63.2%), Europe (28.7%) and other (8.1%).

Sector

Pharmaceuticals

Calendar

2024-04-29 - Q3 2024 Earnings Release (Projected)

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Catalent, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

55.92 USD

Average target price

63.5 USD

Spread / Average Target

+13.56%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CATALENT, INC.	+24.46%	10.12B
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:01 2024-04-26 pm EDT			5-day change	1st Jan Change
55.92 ^USD	+0.22%		+0.79%	+24.46%

Apr. 12	Zacks Investment Research Downgrades Catalent to Underperform From Neutral, Price Target is $48	MT
Apr. 08	Sector Update: Health Care Stocks Decline Late Afternoon	MT